Immune checkpoint inhibitors, such as anti-PD-L1/anti-PD-1, are a standard treatment for patients with several types of tumor; however, their remarkable efficacy may be limited to patients with PD-L1-positive and immune-inflamed (high CD8-positive rate) phenotypes (3,4). This evidence concerns the gene PDCD1 and neoplasm.